Perioperative management of patients who are receiving a novel oral anticoagulant

Internal and Emergency Medicine

Volumn 8, Issue 6, 2013, Pages 477-484

  Liew, Aaron ^a   Douketis, James ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Bleeding; New oral anticoagulants; Perioperative; Thrombosis

Indexed keywords

ANTITHROMBIN; APIXABAN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; DABIGATRAN; DRUG DERIVATIVE; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; RIVAROXABAN; THIOPHENE DERIVATIVE;

AGED; HUMAN; MALE; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; REVIEW; RISK ASSESSMENT; THROMBOEMBOLISM;

AGED; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; HUMANS; MALE; MORPHOLINES; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PYRAZOLES; PYRIDONES; RISK ASSESSMENT; THIOPHENES; THROMBOEMBOLISM;

EID: 84883656881     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-013-0963-5     Document Type: Review

References (33)

1. Coccheri S, Orlando D (2013) New oral anticoagulants in atrial fibrillation: a reappraisal of trial results looking at absolute figures. Intern Emerg Med 8(2): 115-122.
2. Southworth MR, Reichman ME, Unger EF (2013) Dabigatran and postmarketing reports of bleeding. N Engl J Med 368(14): 1272-1274.
3. Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R, American College of Chest P (2012) Perioperative management of antithrombotic therapy: Antithrombotic therapy and prevention of thrombosis, 9th edn: American college of chest physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl): e326S-e350S.
4. Douketis JD (2010) Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management. Curr Pharm Des 16(31): 3436-3441.
5. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, Themeles E, Heidbuchel H, Avezum A, Reilly P, Connolly SJ, Yusuf S, Ezekowitz M (2012) Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (re-ly) randomized trial. Circulation 126(3): 343-348.
6. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A (2010) Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103(6): 1116-1127.
7. Becker RC, Yang H, Barrett Y, Mohan P, Wang J, Wallentin L, Alexander JH (2011) Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban-an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis 32(2): 183-187.
8. Kaplan RC, Tirschwell DL, Longstreth WT Jr, Manolio TA, Heckbert SR, Lefkowitz D, El-Saed A, Psaty BM (2005) Vascular events, mortality, and preventive therapy following ischemic stroke in the elderly. Neurology 65(6): 835-842.
9. Longstreth WT Jr, Bernick C, Fitzpatrick A, Cushman M, Knepper L, Lima J, Furberg CD (2001) Frequency and predictors of stroke death in 5, 888 participants in the cardiovascular health study. Neurology 56(3): 368-375.
10. Martinell J, Jimenez A, Rabago G, Artiz V, Fraile J, Farre J (1991) Mechanical cardiac valve thrombosis. Is thrombectomy justified? Circulation 84(5 Suppl): III70-III75.
11. Carrier M, Le Gal G, Wells PS, Rodger MA (2010) Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 152(9): 578-589.
12. Kaatz S, Douketis JD, Zhou H, Gage BF, White RH (2010) Risk of stroke after surgery in patients with and without chronic atrial fibrillation. J Thromb Haemost 8(5): 884-890.
13. Attaya H, Wysokinski WE, Bower T, Litin S, Daniels PR, Slusser J, Heit JA, McBane RD 2nd (2013) Three-month cumulative incidence of thromboembolism and bleeding after periprocedural anticoagulation management of arterial vascular bypass patients. J Thromb Thrombolysis 35(1): 100-106.
14. McBane RD, Wysokinski WE, Daniels PR, Litin SC, Slusser J, Hodge DO, Dowling NF, Heit JA (2010) Periprocedural anticoagulation management of patients with venous thromboembolism. Arterioscler Thromb Vasc Biol 30(3): 442-448.
15. Tafur AJ, Wysokinski WE, McBane RD, Wolny E, Sutkowska E, Litin SC, Daniels PR, Slusser JP, Hodge DO, Heit JA (2012) Cancer effect on periprocedural thromboembolism and bleeding in anticoagulated patients. Ann Oncol 23(8): 1998-2005.
16. Daniels PR, McBane RD, Litin SC, Ward SA, Hodge DO, Dowling NF, Heit JA (2009) Peri-procedural anticoagulation management of mechanical prosthetic heart valve patients. Thromb Res 124(3): 300-305.
17. Halbritter KM, Wawer A, Beyer J, Oettler W, Schellong SM (2005) Bridging anticoagulation for patients on long-term vitamin-K-antagonists. A prospective 1 year registry of 311 episodes. J Thromb Haemost 3(12): 2823-2825.
18. Malato A, Saccullo G, Lo Coco L, Caramazza D, Abbene I, Pizzo G, Casuccio A, Siragusa S (2010) Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular-weight heparin. J Thromb Haemost 8(1): 107-113.
19. Dunn AS, Spyropoulos AC, Turpie AG (2007) Bridging therapy in patients on long-term oral anticoagulants who require surgery: the prospective peri-operative enoxaparin cohort trial (PROSPECT). J Thromb Haemost 5(11): 2211-2218.
20. Wysokinski WE, McBane RD, Daniels PR, Litin SC, Hodge DO, Dowling NF, Heit JA (2008) Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. Mayo Clin Proc 83(6): 639-645.
21. Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC (2012) Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 126(13): 1630-1639.
22. Spyropoulos AC, Douketis JD (2012) How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 120(15): 2954-2962.
23. Omran H, Bauersachs R, Rubenacker S, Goss F, Hammerstingl C (2012) The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK online bRiDging REgistRy (BORDER). Thromb Haemost 108(1): 65-73.
24. Tafur AJ, McBane R 2nd, Wysokinski WE, Litin S, Daniels P, Slusser J, Hodge D, Beckman MG, Heit JA (2012) Predictors of major bleeding in peri-procedural anticoagulation management. J Thromb Haemost 10(2): 261-267.
25. Jaffer AK, Ahmed M, Brotman DJ, Bragg L, Seshadri N, Qadeer MA, Klein A (2005) Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol. J Thromb Thrombolysis 20(1): 11-16.
26. Kaseno K, Naito S, Nakamura K, Sakamoto T, Sasaki T, Tsukada N, Hayano M, Nishiuchi S, Fuke E, Miki Y, Yamashita E, Kumagai K, Oshima S, Tada H (2012) Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. Circ J 76(10): 2337-2342.
27. Lakkireddy D, Reddy YM, Di Biase L, Vanga SR, Santangeli P, Swarup V, Pimentel R, Mansour MC, D'Avila A, Sanchez JE, Burkhardt JD, Chalhoub F, Mohanty P, Coffey J, Shaik N, Monir G, Reddy VY, Ruskin J, Natale A (2012) Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 59(13): 1168-1174.
28. Kim JS, She F, Jongnarangsin K, Chugh A, Latchamsetty R, Ghanbari H, Crawford T, Suwanagool A, Sinno M, Carrigan T, Kennedy R, Saint-Phard W, Yokokawa M, Good E, Bogun F, Pelosi F Jr, Morady F, Oral H (2013) Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm 10(4): 483-489.
29. Nin T, Sairaku A, Yoshida Y, Kamiya H, Tatematsu Y, Nanasato M, Inden Y, Hirayama H, Murohara T (2013) A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. Pacing Clin Electrophysiol 36(2): 172-179.
30. Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W (2013) Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the subcommittee on control of anticoagulation of the scientific and standardisation committee of the international society on thrombosis and haemostasis. J Thromb Haemost 11(4): 756-760. doi: 1111/jth. 12149.
31. Garcia D, Barrett YC, Ramacciotti E, Weitz JI (2013) Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost 11(2): 245-252.
32. Helin TA, Pakkanen A, Lassila R, Joutsi-Korhonen L (2013) Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories. Clin Chem 59(5): 807-814.
33. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64(3): 292-303.